1. Pink Sheet
  2. >>Pathways & Standards
  3. >>Approval Standards

Califf Hints At Labeling Changes For Opioids And Chronic Pain

 
• By Sarah Karlin-Smith

Califf also said the agency is open to endpoints other than abstinence for new opioid use disorder treatments at the fourth annual NIH HEAL Initiative Investigator Meeting. 

person in pain
The FDA Commissioner Highlighted a New CDC Report Citing ‘No Evidence’ Of Chronic Opioid Benefit When Discussing Potential Labeling Changes. • Source: Shutterstock

US Food and Drug Administration Commissioner Robert Califf offered subtle hints at a recent National Institutes of Health meeting that the agency may eventually try to curtail long-term opioid use through drug labeling.

“It’s well known that we’re looking closely at the labeling of chronic opioids at this point,” Califf said 22 February...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Approval Standards

More from Pathways & Standards

Kisunla Back In The Spotlight As EMA Reconsiders Alzheimer’s Drug Rejection

 
• By Eliza Slawther

It appears that the European Medicines Agency is making progress on its re-examination of Eli Lilly’s Alzheimer’s disease drug Kisunla, following an initial rejection in March based on safety concerns.

Alzheimer’s Drug Leqembi May Be On Course To India, Kisunla In The Wings

 
• By Anju Ghangurde

Key expert panel go-ahead with a trial waiver put’s Eisai's Alzheimer's therapy on track for a debut in India where tailored pricing will be pivotal. Lilly’s Kisunla is also under regulatory review.

Post-Approval, Real-Time Monitoring Will Help Approval Standards, US FDA’s Makary Says

 
• By Sue Sutter

The FDA will use electronic health records to “get eyes” on drugs immediately after approval, Commissioner Martin Makary told the DIA 2025 Global Annual Meeting. He also wants to reduce development time with better communication and new approval pathways.